What is ANI Pharmaceuticals's generics and other — D&A?

ANI Pharmaceuticals (ANIP) reported generics and other — D&A of $0 in Q2 2026.

What does generics and other — D&A mean?

Represents the non-cash allocation of the cost of tangible and intangible assets over their useful lives specifically attributable to the generics segment. This metric is essential for understanding the capital intensity of the segment's manufacturing and intellectual property assets.

ANI Pharmaceuticals (ANIP) Generics and Other — D&A

Screener

Other segment segments

Rare Disease and Brands

$0—

Similar metrics at other companies

LINOther — D&A

$25M+8.7%

SYYOther — D&A

$1M0.0%

NWSOther — D&A

$2M+100%

WEY

WEYSOther — D&A

$178K-12.7%

PFG

PFGCCorporate And Other — D&A

$11.8M-14.5%

DCorporate And Other — D&A

$25M+13.6%

Other financials

Income statement

See full

Revenue$266.0M+25.9%

Gross profit$165.9M+21.3%

Operating income$40.5M+191%

Net income$24.7M+189%

EPS (diluted)$1.05+192%

Balance sheet

See full

Cash & equivalents$360.2M+65.4%

Total debt$301.5M-4.2%

Total equity$597.2M+36.7%

Total assets$1.5B+11.3%

Cash flow

See full

Operating cash flow$56.7M-25.3%

CapEx$3.1M-23.9%

Free cash flow$53.6M-25.3%

Valuation

See full

Market cap$1.88B+25.6%

Enterprise value$1.82B+14.3%

P/E17.3×—

P/S1.9×-0.1×

Profitability

See full

Gross margin60.4%-0.7pp

Operating margin15.4%—

Net margin11.1%+10.0pp

FCF margin17.7%+0.9pp

Returns & leverage

See full

Return on equity21%+19.1pp

Debt / equity0.5×-0.2×

Current ratio2.9×+0.4×

Where this comes from

Reported directly by ANI Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.

The source filing: ANI Pharmaceuticals’s 10-Q, filed August 7, 2026.

Filed: Aug 7, 2026, 7:01 AM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001023024-26-000069

Line item	Three Months Ended June 30, 2026	Three Months Ended June 30, 2025	Six Months Ended June 30, 2026	Six Months Ended June 30, 2025
Cost of sales (excluding depreciation and amortization)	100,158	74,615	193,740	147,652
Research and development	14,747	16,535	25,347	27,099
Selling, general, and administrative	91,661	81,771	165,316	158,299
Depreciation and amortization	19,640	23,281	40,559	46,172
Contingent consideration fair value adjustment	(622)	1,277	(804)	(10,815)
Total Operating Expenses, net	225,584	197,479	424,158	368,407
Operating income	40,460	13,892	79,348	40,086
Other (expense) income, net

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is ANI Pharmaceuticals's generics and other — D&A?: ANI Pharmaceuticals (ANIP) reported generics and other — D&A of $0 in Q2 2026.
What does generics and other — D&A mean?: Represents the non-cash allocation of the cost of tangible and intangible assets over their useful lives specifically attributable to the generics segment. This metric is essential for understanding the capital intensity of the segment's manufacturing and intellectual property assets.